Microsatellite instability (MSI) / defective DNA mismatch repair (dMMR) represent an important molecular alteration with diagnostic, prognostic and predictive value. The increasing interest towards this genetic alteration is given to the high response rate of MSI/dMMR tumors to immunotherapy. There are different cancers in the periampullary region that can harbor MSI/dMMR, and significant morphological-molecular correlates should be acknowledged in this district: 1) Pancreatic ductal adenocarcinoma (PDAC): in this tumor category, the prevalence of MSI/dMMR is about 1-2%, and medullary and colloid variants are the most typically involved; 2) Ampullary adenocarcinoma: here the prevalence of MSI/dMMR is up to 18%. In this neoplastic group, MSI/dMMR is more commonly found in the intestinal subtype; 3) Pancreatic acinar cell carcinoma: here the prevalence of MSI/dMMR is up to 14%; 4) pancreatic and ampullary neuroendocrine carcinoma: in this tumor category, the prevalence of MSI/dMMR is up to 5-8%, and this molecular alteration should be assessed also in cases of mixed neuroendocrine-non neuroendocrine neoplasms. Given the clinical importance of MSI/dMMR and its not-negligible prevalence among the different carcinomas arising in this district, its assessment should become part of the routine diagnostic workflow at least for the most typical histotypes. The test of choice is represented by immunohistochemistry for PDAC and ampullary carcinomas, and by direct molecular analyses including MSI-based polymerase chain reaction and next-generation sequencing for acinar cell and neuroendocrine carcinomas.

Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology and clinical implications

Luchini Claudio;Scarpa Aldo
2023-01-01

Abstract

Microsatellite instability (MSI) / defective DNA mismatch repair (dMMR) represent an important molecular alteration with diagnostic, prognostic and predictive value. The increasing interest towards this genetic alteration is given to the high response rate of MSI/dMMR tumors to immunotherapy. There are different cancers in the periampullary region that can harbor MSI/dMMR, and significant morphological-molecular correlates should be acknowledged in this district: 1) Pancreatic ductal adenocarcinoma (PDAC): in this tumor category, the prevalence of MSI/dMMR is about 1-2%, and medullary and colloid variants are the most typically involved; 2) Ampullary adenocarcinoma: here the prevalence of MSI/dMMR is up to 18%. In this neoplastic group, MSI/dMMR is more commonly found in the intestinal subtype; 3) Pancreatic acinar cell carcinoma: here the prevalence of MSI/dMMR is up to 14%; 4) pancreatic and ampullary neuroendocrine carcinoma: in this tumor category, the prevalence of MSI/dMMR is up to 5-8%, and this molecular alteration should be assessed also in cases of mixed neuroendocrine-non neuroendocrine neoplasms. Given the clinical importance of MSI/dMMR and its not-negligible prevalence among the different carcinomas arising in this district, its assessment should become part of the routine diagnostic workflow at least for the most typical histotypes. The test of choice is represented by immunohistochemistry for PDAC and ampullary carcinomas, and by direct molecular analyses including MSI-based polymerase chain reaction and next-generation sequencing for acinar cell and neuroendocrine carcinomas.
AVC; MSI; Microsatellite; PDAC; dMMR; mismatch; pancreatic ductal adenocarcinoma
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1069527
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact